VisionGate offers the earliest detection of lung cancer when the chance for a cure is the best. Our quick, non-intrusive test is based on 3D cellular imaging and AI.

The Cell-CT

VisionGate Leading Research Against Lung Cancer

At the Forefront of Novel Science

VisionGate is a biotechnology company leading the battle against lung cancer in high-risk patients using simple non-intrusive testing, 3D cell imaging, and a patented AI-powered cancer detection process.

Our Breakthrough
Technology

VisionGate offers the earliest detections of lung cancer when the chance for a sure is the best. Our quick non-intrusive test is based on 3D cellular imaging and Ai.

Non-Intrusive
Testing

Sputum (phlegm) samples from a deep cough (LuCED° Lung Test) are collected over a three-day period using a take-home test kit.

Patented Cell-CT Imaging

High-resolution 3D images of sputum cells measure hundreds of disease indicators.

AI-Powered
Cancer Detection

AI-classifiers are trained to identify abnormal cells. The result is highly accurate cell classification.

VisionGate
Potential

VisionGate’s intellectual property is comprised of 35 patents with 5 more pending.

Please contact us for investment opportunities.

visiongate potentional 35 patents 51 billion

Our Clinical Partners

Feinber School of Medicine
northwestern university feinberg school of medicine logo

VisionGate Blog

Learn more about the our latest news, patents, partnerships, ongoing research, and how early detection can help cure lung cancer.

News
Patents
Publications
Research